Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
DRUG
DRUG News & Events
-
Add to Watchlist
Trade DRUG
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
DRUG News
Bright Minds Biosciences Prices 1.945M Shares at $90 for $175.05M Offering
Jan 08 2026
Globenewswire
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
Jan 07 2026
Benzinga
Bright Minds Biosciences Launches $100 Million Public Offering
Jan 07 2026
Benzinga
Barclays Cuts BJ's Wholesale Price Target to $90
Jan 07 2026
Benzinga
Bright Minds Reports Phase 2 BREAKTHROUGH Trial Results for BMB-101, 73.1% Seizure Reduction
Jan 06 2026
Benzinga
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Bright Minds' BMB-101 Shows Significant Seizure Reduction in Phase 2 Trial
Jan 06 2026
Globenewswire
Bright Minds Biosciences to Report Phase 2 BMB-101 Results on January 6, 2026
Jan 06 2026
NASDAQ.COM
Show More News
DRUG Events
01/08 06:30
Deal Size Increased to $175M in Common Stock
The deal size was increased to $175M in common stock from $100M in common stock. Jefferies, TD Cowen, Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.
Show More Events
DRUG Monitor News
Bright Minds Biosciences stock drops after public offering announcement
Jan 08 2026
Bright Minds Biosciences Inc. Surges on BMB-101 Phase 2 Results
Jan 06 2026
DRUG Earnings Analysis
No Data
People Also Watch
